Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of U.S. drug maker Cephalon
So what: The all-cash offer values Cephalon at $73 per share and represents a 25% premium to its closing price Tuesday. Valeant is making the move to expand its offering into cancer drugs and other fields, and judging from the stock's 11% pop, Mr. Market seems to agree wholeheartedly with the strategy.
Now what: Cephalon shares have soared past the $73 offer price today, so it's obvious that shareholders expect a higher bid coming. Of course, with Valeant CEO Michael Pearson making it very clear that he will "remain very disciplined on price," I'd consider scaling back any position in Cephalon. Given the risk that Valeant ends up walking away from the deal altogether, locking in some gains just seems like the prudent thing to do.
Interested in more info on Cephalon? Add it to your watchlist.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
More from The Motley Fool
Investing 101: The Most Undervalued Golden Cross Breakout Stocks
Consider these value plays.
What's All the Fuss About Zalicus?
Stock's up on an Oppy upgrade.
This Week's 5 Smartest Stock Moves
There's always time to look at the bright side of life.